Interstitial Lung Disease Pipeline Insight 2026: 120+ Companies Advancing Novel Therapies for Pulmonary Fibrosis and Lung Scarring Disorders | DelveInsight

DelveInsight's "Interstitial Lung Diseases Pipeline Insight, 2026" report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Interstitial Lung Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Interstitial Lung Disease Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/report-store/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from the Interstitial Lung Disease Pipeline Report
• DelveInsight's Interstitial Lung Disease pipeline report depicts a robust space with approx. 120+ key active players working to develop 120+ pipeline therapies for Interstitial Lung Disease treatment.
• Pfizer is among the Interstitial Lung Disease companies with a candidate in the most advanced stage of development, Phase III.
• The leading Interstitial Lung Disease companies include Daewoong Pharmaceutical, PureTech, Bristol-Myers Squibb, and others.
• Promising Interstitial Lung Disease therapies include DWN12088, LYT-100, BMS-986278, and others.
• The Interstitial Lung Disease Pipeline report provides the disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. It also highlights the unmet needs with respect to Interstitial Lung Disease.

Interstitial Lung Disease Overview
Interstitial lung disease, also referred to as diffused parenchymal disease, comprises a heterogeneous group of disorders characterized by fibrosis, or scarring, of the lungs. These conditions are classified on the basis of histopathological, radiologic, and clinical parameters.

The classification system used to describe interstitial lung disease groups conditions based on their causes, distinguishing exogenous from endogenous factors, while cases without an identifiable cause fall under the idiopathic/primary category, which relies on histopathological and radiologic assessment. Many subsets of the disease are of unknown etiology, yet they ultimately share a common pattern of development. The morphological changes observed histologically arise from a sequence of inflammation within the lung parenchyma, the compartment responsible for gas exchange, comprising the alveoli, alveolar ducts, and bronchioles. This region hosts various proteins and pro-fibrotic elements that, after repeated cycles of activation, lead to the accumulation of connective tissue. The trigger can be a known agent deposited within lung tissue, or in some cases, fibrosis may arise spontaneously.

The "Interstitial Lung Disease - Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present scenario and growth prospects across the indication. A detailed picture of the Interstitial Lung Disease pipeline landscape is provided, including the disease overview and treatment guidelines. The assessment covers in-depth commercial and clinical evaluation of pipeline products under development, along with detailed drug descriptions covering mechanism of action, clinical studies, NDA approvals (if any), and product development activities including technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other product-related details.

From emerging drug candidates to competitive intelligence, the Interstitial Lung Disease Pipeline Report covers it all @ https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Interstitial Lung Disease Emerging Drugs
• DWN12088: Daewoong Pharmaceutical
DWN12088 is an investigational therapy for idiopathic pulmonary fibrosis (IPF) that has shown promising anti-fibrotic properties and appeared safe and well-tolerated in a recently completed Phase I clinical trial enrolling healthy volunteers. It limits the body's ability to produce collagen by preventing an enzyme called glutamyl-prolyl-tRNA synthetase from adding proline to the protein's sequence. The FDA designated DWN12088 as an orphan drug for IPF in 2019. The drug is currently in the Phase II stage of clinical trial evaluation to treat IPF.

• LYT-100: PureTech
LYT-100 is PureTech's most advanced wholly-owned therapeutic candidate. A deuterated form of pirfenidone, an approved anti-inflammatory and anti-fibrotic drug, LYT-100 is being advanced for the potential treatment of conditions involving inflammation and fibrosis, including lung disease such as IPF and potentially other PF-ILDs and Long COVID respiratory complications, as well as disorders of lymphatic flow such as lymphedema. PureTech completed a Phase 1 multiple ascending dose and food effect study in healthy volunteers and found it well-tolerated at all doses tested. The company is evaluating LYT-100 in a Phase 2 trial for Long COVID respiratory complications as well as in a Phase 2a proof-of-concept study in breast cancer-related, upper limb secondary lymphedema. PureTech is also advancing LYT-100 for IPF and potentially other PF-ILDs, with registration-enabling studies planned.

• BMS-986278: Bristol-Myers Squibb
BMS-986278, a lysophosphatidic acid receptor antagonist (LPA1), is being developed by Bristol-Myers Squibb for the treatment of idiopathic pulmonary fibrosis. It is a potent and complete antagonist of LPA action at LPA1-mediated Gi, Gq, G12, and β-arrestin signaling pathways in both cells heterologously expressing human LPA1 and in primary human lung fibroblasts. It is currently in the Phase II stage of clinical trial evaluation.

Want to know which companies are leading innovation in Interstitial Lung Disease? Dive into the full pipeline insights @ https://www.delveinsight.com/report-store/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

The Interstitial Lung Disease Pipeline Report Provides Insights Into
• Detailed insights about companies developing therapies for Interstitial Lung Disease, along with the aggregate therapies developed by each company.
• An assessment of therapeutic candidates segmented into early-stage, mid-stage, and late-stage development.
• Analysis of collaborations, licensing, mergers and acquisitions, and funding activity.
• Drug profiles covering mechanism of action, clinical studies, NDA approvals (if any), technology, designations, and other product-related details.
• Coverage of inactive (discontinued) candidates in the pipeline.

Interstitial Lung Disease Companies
Daewoong Pharmaceutical, PureTech, Bristol-Myers Squibb, Pfizer, and others.

From emerging drug candidates to competitive intelligence, the Interstitial Lung Disease Pipeline Report covers it all @ https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Interstitial Lung Disease Phases
DelveInsight's report covers around 120+ products under different phases of clinical development:
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
The Interstitial Lung Disease pipeline report provides the therapeutic assessment of pipeline drugs by route of administration. Products have been categorized under various ROAs such as:
• Oral
• Intravenous
• Subcutaneous

Molecule Type
Interstitial Lung Disease products have been categorized under various molecule types such as:
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Gene therapy

Scope of the Interstitial Lung Disease Pipeline Report
• Coverage: Global
• Interstitial Lung Disease Companies: Daewoong Pharmaceutical, PureTech, Bristol-Myers Squibb, Pfizer, and others.
• Interstitial Lung Disease Therapies: DWN12088, LYT-100, BMS-986278, and others.
• Interstitial Lung Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what's next for the Interstitial Lung Disease Treatment landscape in this detailed analysis @ https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Introduction
2. Executive Summary
3. Interstitial Lung Disease: Overview
4. What is Interstitial Lung Disease?
5. Types of Interstitial Lung Disease
6. Causes
7. Epidemiology and Risk Factors
8. Disease Management
9. Pipeline Therapeutics
10. Comparative Analysis
11. Therapeutic Assessment
12. Interstitial Lung Disease - DelveInsight's Analytical Perspective
13. Late Stage Products (Phase III)
14. Mid Stage Products (Phase II)
15. Early Stage Products (Phase I)
16. Preclinical Stage Products
17. Inactive Products
18. Interstitial Lung Disease Key Companies
19. Interstitial Lung Disease Key Products
20. Interstitial Lung Disease - Unmet Needs
21. Interstitial Lung Disease - Market Drivers and Barriers
22. Interstitial Lung Disease - Future Perspectives and Conclusion
23. Interstitial Lung Disease Analyst Views
24. Appendix

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.